Psychiatry and Neurology, Neurology · Plano, TX
NPI
1275755399
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
5425 W Spring Creek Pkwy Ste 275
Plano, TX, 75024
Phone (972) 403-8184
Groups this clinician bills Medicare through
Medicare paid, 2024
$231K
961 services
Medicare patients, 2024
63
Average age 62
Drug cost, 2024
$2.0M
810 prescriptions
Company payments, 2025
$38K
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Annette F Okai was code A9575 (injection, gadoterate meglumine, 0.1 ml), 173 times for 12 patients. In total Annette F Okai billed 961 services in 19 codes, and Medicare paid $231K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| A9575 Injection, gadoterate meglumine, 0.1 ml | Office | 173 | 12 | $0.09 | $15.5 |
| 99214 Office E&M - Established | Office | 108 | 58 | $72.19 | $7,797 |
| 70553 MRI/MRA - Head and Neck | Office | 11 | 11 | $183.67 | $2,020 |
By year: 2023 $18K for 603 services; 2024 $231K for 961 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 45 | 41 | $7.33 | $330 |
Medicare prescription drug claims, 2024
In 2024, the drug Annette F Okai prescribed most often to Medicare patients was Teriflunomide, with 98 prescriptions and refills. In total Annette F Okai wrote 810 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Teriflunomide Generic | 98 | 104 | 12 | $457K |
| Gabapentin Generic | 97 | 211 | 26 | $2,625 |
| Baclofen Generic | 84 | 202 | 27 | $2,792 |
| Dalfampridine Er Dalfampridine | 52 | 102 | 11 | $42K |
| Meloxicam Generic | 37 | 37 | Under 11 | $89.34 |
| Soliris Eculizumab | 28 | 28 | Under 11 | $721K |
| Pregabalin Generic | 25 | 43 | Under 11 | $846 |
| Tramadol Hcl Generic | 24 | 24 | Under 11 | $117 |
| Tizanidine Hcl Generic | 21 | 50 | Under 11 | $132 |
| Kesimpta Pen Ofatumumab | 20 | 20 | Under 11 | $208K |
| Bupropion Xl Bupropion Hcl | 18 | 26 | Under 11 | $193 |
| Carbamazepine Generic | 17 | 27 | Under 11 | $829 |
| Hydroxyzine Hcl Generic | 16 | 16 | Under 11 | $44.96 |
| Amantadine Amantadine Hcl | 16 | 28 | Under 11 | $402 |
| Duloxetine Hcl Generic | 15 | 29 | Under 11 | $235 |
Brand drugs: 75 claims; generic drugs: 735 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Annette F Okai $38K ($36K in general payments such as food, travel and fees and $1,515 for research) from 29 companies. The largest payer was Genentech USA, Inc. with $15K.
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. ROG.SW | 27 | $15K |
| Merck KGaA MRK.DE | 2 | $11K |
| Genzyme Corporation SNY | 4 | $2,790 |
| Invivyd Inc IVVD | 1 | $2,135 |
| F. Hoffmann-La Roche AG ROG.SW | 2 | $1,515 |
| Genentech, Inc. ROG.SW | 2 | $1,353 |
| EMD Serono, Inc. MRK.DE | 11 | $657 |
| Abbvie Inc. ABBV | 28 | $575 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $479 |
| TG Therapeutics, Inc. TGTX | 5 | $297 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.